Introduction
============

Endometrial cancer is the most common gynecological malignancy and the fourth most common type of cancer in women ([@b1-etm-0-0-3251]--[@b3-etm-0-0-3251]), following breast, lung and colorectal cancer. The incidence and mortality rate of endometrial cancer is increasing in developing and developed countries ([@b3-etm-0-0-3251]--[@b6-etm-0-0-3251]), although the rates of several other types of cancer have plateaued or decreased in the last decade ([@b5-etm-0-0-3251]). Over the past decades, much has been discovered about the genetics and lifestyle and environmental factors that affect endometrial cancer ([@b7-etm-0-0-3251],[@b8-etm-0-0-3251]). The most significant risk factors for endometrial cancer and its precursor, endometrial hyperplasia, are unopposed estrogen, a sedentary lifestyle and obesity ([@b5-etm-0-0-3251],[@b9-etm-0-0-3251]). Obesity is a major public health issue and continues to increase worldwide. By 2030, the rate of obesity is anticipated to reach \~50% of the population of the US and 30% in Europe ([@b10-etm-0-0-3251]). Obesity not only significantly increases the risk of insulin resistance and type-2 diabetes but it has also been identified as a risk factor for several types of cancer, such as endometrial cancer ([@b10-etm-0-0-3251]). Previous studies demonstrated that obesity is one of the strongest risk factors that exists for numerous types of cancer, including breast, colorectal, kidney, endometrial, ovarian, pancreatic and liver cancer ([@b5-etm-0-0-3251],[@b11-etm-0-0-3251]--[@b13-etm-0-0-3251]). In addition, endometrial cancer was the first type to be shown to be associated with obesity ([@b5-etm-0-0-3251]).

Adipose tissue functions as an energy storage and also as a highly active and large source of endocrine and metabolic activity ([@b7-etm-0-0-3251],[@b10-etm-0-0-3251]). Adipokines are produced by adipose tissue and include leptin, resistin, adiponectin (APN), serpin, plasminogen activator inhibitor-1, retinol binding protein 4 and other numerous cytokines including tumor necrosis factor-α and interleukin receptor agonists (IL-1, IL-6, IL-8 and IL-10) ([@b14-etm-0-0-3251],[@b15-etm-0-0-3251]). APN is the most abundant adipokine that is secreted mainly from visceral adipose tissue and only from mature adipocytes. It is an endogenous insulin-sensitizing hormone, and is linked to obesity, metabolic syndrome, insulin resistance, type-2 diabetes and inflammation in addition to several other types of cancer. APN has anti-diabetic, anti-angiogenic, anti-inflammatory and anti-atherogenic properties ([@b10-etm-0-0-3251],[@b14-etm-0-0-3251]--[@b16-etm-0-0-3251]), which are known to inhibit cell proliferation, promote apoptosis and angiogenesis in tumor biology ([@b17-etm-0-0-3251]). Furthermore, APN inhibits carcinogenesis directly and indirectly by regulating hormone and cytokine levels.

Circulating APN may potentially be a protective factor for endometrial cancer. Retrospective and prospective studies have investigated the association of circulating APN levels with the risk of endometrial cancer. Although the majority of the studies demonstrated a negative association, several studies demonstrated that there is no association between the two. Therefore, the association between the two remains to be clarified. Nevertheless, the incidence of endometrial cancer has risen in each year over the past few years and the major problem facing treatment is its late diagnosis. By the time that it gets diagnosed, the vast majority of patients have advanced to the late stages of cancer, and the outcome of clinical treatment is poor. Therefore, is an interest amongst cancer researchers to identify convenient and effective molecular markers and methods in order to diagnose cancer at the early stages. Blood is the most readily available sample and it is an ideal specimen for identifying molecular markers of cancer. Circulating APN may be a novel molecular marker or anti tumor factor that may provide a feasible method for early detection and prevention of endometrial cancer which may be important in its diagnosis and therapy. To the best of our knowledge, there have been a few systematic reviews conducted to evaluate whether low APN levels increase the risk of endometrial cancer. Therefore, this meta-analysis was performed to summarize all of the data available and to provide a quantitative assessment of the risk.

Patients and methods
====================

### Characteristics of included studies

A total of 18 studies were included in the final analysis ([@b18-etm-0-0-3251]--[@b35-etm-0-0-3251]). The detailed steps of the search results are provided in [Fig. 1](#f1-etm-0-0-3251){ref-type="fig"}. These 18 studies were published between 2003 and 2014, and included 2,337 women with endometrial cancer and 3,355 controls. Out of those 18 studies, 11 studies were conducted in Asia (China and Japan), 4 in North America (USA and Canada), and 3 in Europe (Greece, Poland and Romania). The quality score of the studies ranged from 5 to 8 stars (Newcastle-Ottawa Scale) ([@b36-etm-0-0-3251]). There were only 7 studies providing the cancer grade data ([@b22-etm-0-0-3251]--[@b24-etm-0-0-3251],[@b28-etm-0-0-3251],[@b30-etm-0-0-3251],[@b32-etm-0-0-3251],[@b34-etm-0-0-3251]). The main characteristics of the included studies are summarized in [Tables I](#tI-etm-0-0-3251){ref-type="table"} and [II](#tII-etm-0-0-3251){ref-type="table"}.

### Search strategy

The US National Library of Medicine\'s PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed/>) was searched using the terms 'endometrial cancer' 'endometrial carcinoma' 'adiponectin' 'Adipo' and 'APN' to assess the possibility of conducting the present study. A comprehensive literature search was conducted in PubMed, SpringerLink (<http://link.springer.com/>) and Google Scholar (<http://scholar.google.com.hk>) up to June 2014 using the terms 'adiponectin' or 'Adipo' or 'APN' and 'endometrial cancer' or 'endometrial carcinoma'. The search was limited to English and Chinese. Additional studies were also identified by manually searching references of original studies and by reviewing articles on the topic. Eligible studies in the current meta-analysis were those of case-control design, which reported the correlation between circulating APN levels and endometrial cancer. The present study was performed in accordance to the MOOSE guidelines for meta-analysis ([@b37-etm-0-0-3251]).

### Data extraction

Data were independently extracted by two researchers. For each eligible study, the following information was recorded: The first author, year of publication, ethnicity, study size and number of cases, APN measurement method, total APN mean and standard deviation ([@b38-etm-0-0-3251]), menopausal status, control source and health status and language of publication. For one study ([@b18-etm-0-0-3251]) that provided the outcomes in medians and interquartile ranges, these were converted to the means and standard deviations ([@b39-etm-0-0-3251]). Any missing data from studies was obtained by communicating with the authors. The quality of each study was assessed by Newcastle-Ottawa Scaling ([@b36-etm-0-0-3251]).

### Statistical analysis

The standardized mean differences (SMDs) of the total circulating APN were calculated for all of the eligible studies in the meta-analysis, as they were measured in different units across studies. A fixed effects model was used to pool the data when the P-value of the Q-test was ≥0.05; otherwise a random effects model was selected ([@b40-etm-0-0-3251]). The Q and I*2* statistics were used in order to evaluate the heterogeneity amongst the results of the studies. When I*2*\>50%, the heterogeneity was considered significant ([@b41-etm-0-0-3251]). A sensitivity analysis was conducted by exclusion of the studies; subgroup analysis according to study size, study quality, ethnicity, menopausal status, control source, language of publication and laboratory assay. Cumulative meta-analyses were performed in order to observe the change of the association with time and sample size ([@b42-etm-0-0-3251]). Furthermore, a funnel plot and Egger\'s test was used to assess the publication bias, and P\<0.05 was considered to indicate a statistically significant difference ([@b43-etm-0-0-3251],[@b44-etm-0-0-3251]). All the analyses were performed using Stata software version 11.0 (StataCorp LP, College Station, TX, USA).

Results
=======

### Main analysis

The results of the meta-analysis of the association between circulating APN levels and endometrial cancer included 20 data sets from 18 studies ([Fig. 2](#f2-etm-0-0-3251){ref-type="fig"}). It was identified that women with endometrial cancer had significantly lower APN levels in the pooled analysis using a random-effects model \[SMD (95% CI), −1.96 (−2.60, −1.31); P\<0.001\], yet with significant heterogeneity among studies (I*2*\>50%). Egger\'s test for publication bias did not provide evidence of significant effect (P\>0.05). There were 7 studies providing cancer grade. On comparison of cancer grades, APN values were not statistically different between the different grades of endometrial cancer \[G1 vs. G3, 1.02 (−0.68, 2.72), P\>0.05; G1 vs. G2, 0.34 (−0.86, 1.54), P\>0.05\].

### Subgroup/sensitivity analysis

Sensitivity analysis was performed by deleting one study at a time, and the pooled SMD for the remaining studies was calculated in order to check the influence of the removed data. The results revealed that 5 studies were the key contributors to the heterogeneity among studies ([Fig. 3](#f3-etm-0-0-3251){ref-type="fig"}) ([@b19-etm-0-0-3251],[@b23-etm-0-0-3251],[@b24-etm-0-0-3251],[@b32-etm-0-0-3251],[@b33-etm-0-0-3251]). Although heterogeneity existed after excluding these studies, the results revealed no significant alteration with an SMD (95% CI) of −1.288 (−1.655, −0.922) and P\<0.001. To identify potential sources of heterogeneity between studies, subgroup analysis was also performed by study size and quality, ethnicity, menopausal status, language of publication, control source and laboratory assay. The heterogeneity existed in subgroup analysis, and the association between small-sized and low-quality studies was identified to be stronger than in large-sized and high-quality studies. The present study suggested that the difference in study size and quality of the cases and the controls was due to the heterogeneity amongst the studies. The total effect values in Asia, Europe and North America were −2.48 (−3.97, −0.99), −0.52 (−0.90, −0.14) and −1.71 (−2.60, −0.82), respectively. The total effect value of postmenopausal endometrial cancer patients was −2.27 (−4.36, −0.18), which revealed that the high APN level was associated with decreased endometrial cancer risk in postmenopausal women (P\<0.05). However, there was no association in premenopausal endometrial cancer \[-1.52 (−3.49, 0.45), P\>0.05\]. Furthermore, the risk of low APN level to endometrial cancer did not differ substantially by laboratory assay, control sources and language of publication. These results are presented in [Table III](#tIII-etm-0-0-3251){ref-type="table"}.

### Cumulative meta-analysis

To further observe the change in the association between circulating APN levels and endometrial cancer, the cumulative meta-analysis was performed and sorted by year and total size ([Figs. 4](#f4-etm-0-0-3251){ref-type="fig"} and [5](#f5-etm-0-0-3251){ref-type="fig"}). Data analysis suggests that the risk of low APN levels to endometrial cancer was not observed all the time and requires further study in order to confirm this result. Nevertheless, patients with endometrial cancer were observed to have markedly lower APN values compared with the controls.

### Estimation of publication bias

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias. The Funnel plot revealed a slight asymmetry in the distribution but Egger\'s regression test suggested no significant asymmetry of the Funnel plot (P=0.229).

Discussion
==========

The majority of previous studies have suggested that there is an independent and negative association of circulating APN with endometrial cancer, however, a number of studies indicated no association ([@b29-etm-0-0-3251],[@b45-etm-0-0-3251],[@b46-etm-0-0-3251]). Since the results of a single study may be affected by numerous factors, the present study included 18 studies, which comprised a total of 4,186 participants and 1,823 cases, to further detect the risk of low APN in endometrial cancer by reducing the bias and by increasing the efficiency of the statistics. In the present study, significantly low APN levels were observed in women with endometrial cancer in the pooled analysis, although there was clear heterogeneity across the studies. When the cancer grades were compared, the risk of low APN to endometrial cancer was not significantly different between grades of endometrial cancer, which was not identical with previous studies ([@b22-etm-0-0-3251]--[@b24-etm-0-0-3251],[@b28-etm-0-0-3251],[@b30-etm-0-0-3251],[@b32-etm-0-0-3251],[@b34-etm-0-0-3251]). In the subgroup and sensitivity analyses, there was significant heterogeneity among studies. The significant association existed in all of the pooled analysis, but not in premenopausal women, the radioimmunoassay or patients without EC from control sources. The risk was identified to be stronger in small-sized and low-quality studies than in large-sized and high-quality studies, suggesting that the effect of APN may be strongly affected by the small-sized and low-quality studies. A previous study indicated that high APN levels may decrease the risk of postmenopausal endometrial cancer ([@b28-etm-0-0-3251]). However, there was no significant difference in premenopausal women, which was in contrast with various other studies ([@b29-etm-0-0-3251],[@b47-etm-0-0-3251],[@b48-etm-0-0-3251]). Since the female gender and hormone levels are recognized risk factors for endometrial cancer and the mechanism remains unclear, the risk of low APN levels on endometrial cancer of pre- and postmenopausal women is difficult to fully investigate. In the other subgroups, no significant differences were observed in the risk of low APN to endometrial cancer. In the cumulative meta-analysis that was undertaken in the present study, the risk of low APN to endometrial cancer changed with time and sample size. Therefore, further studies are required in order to identify the risk.

The mechanisms of action of APN in regards to endometrial cancer have not yet been fully elucidated. APN is a link between obesity and obesity-associated malignancies, mainly on the basis of the finding that APN levels are lower in patients who suffer with these types of cancer. AdipoR1/AdipoR2 are the two different receptor isoforms of APN, which are expressed in fat and muscle tissues in humans. The expression levels of these receptors are regulated by insulin and peroxisome proliferator-activated receptors (PPAR)-α and -γ. It has been demonstrated that the receptors have lower expression levels in subcutaneous and visceral adipose tissues than in skeletal muscle. Furthermore, previous studies confirmed that there was a strong, inverse and consistent association between circulating APN and obesity, insulin resistance and inflammatory markers, including C-reactive protein and fibrinogen. Thus, several case-control studies demonstrated that APN receptors, particularly AdipoR1, are upregulated in malignancies such as endometrial cancer. Furthermore, there is a possibility that APN affects cancer cell proliferation and tumor formation and progression directly by receptor-mediated stimulation of signaling pathways and indirectly by moderating insulin sensitivity. APN binding to its receptors (AdipoR1/AdipoR2) may exert direct effects on these malignancy signaling pathways, mainly 5′ adenosine monophosphate-activated protein kinase (AMPK), but also PPAR-α, mitogen-activated protein kinase and nuclear factor (NF)-κB. AMPK activation regulates cell proliferation, decreases the expression of transcriptional regulators and positively regulates important proteins associated with controlling cell cycle arrest and apoptosis. It is suggested that APN may affect tumor cells by directly inhibiting pro-angiogenic factors, including basic fibroblast growth factor and interleukin-8 produced by tumors, or platelet-derived growth factor BB produced by endothelial cells. APN also exerts an indirect action by insulin-sensitizing, anti-inflammatory and anti-angiogenic effects. Hyperinsulinemia, obesity and physical inactivity result in higher concentrations of circulating sex hormone-binding globulin and insulin-like growth factor 1, which leads to increased cell proliferation, decreased apoptosis and increased inflammation. *In vitro* studies to date reveal that APN decreases cell viability and proliferation in endometrial cancer. Although these results are promising, further studies are required in animals and humans to elucidate the effects of circulating APN and its association with endometrial cancer.

To the best of our knowledge, the present study was the first to perform a meta-analysis that adds to the current understanding of the association between circulating APN levels and endometrial cancer. The present study included a large number of cases and controls that significantly increased its statistical power. However, several limitations in the study should be addressed. The study is based on observational studies (case-control) and is particularly vulnerable to potential biases (information or selection bias) and bias in the original studies. The significant heterogeneity observed across the results of the study reduces the reliability of the observations, suggesting different outcomes across studies with different patients, controls, methods and measurements. All eligible studies were published in English and Chinese and a number of relevant studies in other languages were not included. Additionally, the conversion of non-normally distributed statistics maybe have been less accurate than if individual data had been available. Finally, the sample sizes for certain subgroup analyses were small. Therefore, the conclusions drawn from the results of this meta-analysis should be regarded cautiously.

In summary, the present study indicated that low circulating APN levels may increase the risk of endometrial cancer, although there was a significant heterogeneity across the studies, and that the high APN level may decrease the risk of endometrial cancer in postmenopausal women. As APN is theorized to affect cell proliferation, tumor formation and progression of endometrial cancer, it may be a promising tool in endometrial cancer prevention, diagnosis and therapy as a simple biomarker. However, further studies are required in order to elucidate the mechanisms of APN.

The authors are very grateful to Dr Petridou for providing the additional data requested. This present research was supported by the Graduate Innovation Fund of Jilin University (grant no. 2014113).
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###### 

Characteristics of eligible studies in the meta-analysis.

                        Adiponectin level, mean ± SD                                                                                                                                                                                        
  --------------------- ------------------------------ -------- ------ --------- ----------------- ------------------ ------- --- ------- ------------------------------------------------------------------ --------- -------------------- -----------------------
  Friedenreich, 2012    N Am                           None     NS     514/962   11.6±1.6          14.6±1.9           ≥100    8   Both    Population, healthy                                                English   ELISA                ([@b18-etm-0-0-3251])
  Ashizawa, 2010        Asian                          None     FIGO   146/150   6.2±0.4           9.0±0.4            ≥100    8   Post-   Hospital, healthy                                                  English   ELISA                ([@b19-etm-0-0-3251])
  Er, 2011              Asian                          None     FIGO   49/44     8±4               13±5               \<100   7   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b20-etm-0-0-3251])
  Friedenreich, 2011    N Am                           None     NS     121/262   10.1±5.1          13.8±7.4           ≥100    8   Pre-    Population, healthy                                                English   ELISA                ([@b21-etm-0-0-3251])
  Friedenreich, 2011    N Am                           None     NS     394/700   14.5±8.5          18.1±9.5           ≥100    8   Post-   Population, healthy                                                English   ELISA                ([@b21-etm-0-0-3251])
  Fu, 2012              Asian                          None     NS     20/30     6.7±1.1           10.0±1.4           \<100   7   Pre-    Hospital, healthy                                                  Chinese   ELISA                ([@b22-etm-0-0-3251])
  Fu, 2012              Asian                          None     NS     15/30     9.2±1.0           10.0±1.4           \<100   7   Post-   Hospital, healthy                                                  Chinese   ELISA                ([@b22-etm-0-0-3251])
  Wang, 2013            Asian                          None     FIGO   135/135   15.3±2.3          6.8±1.1            ≥100    8   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b23-etm-0-0-3251])
  Li, 2011              Asian                          Higher   FIGO   62/20     6.86±1.09         15.24±2.32         \<100   6   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b24-etm-0-0-3251])
  Ma, 2013              Asian                          None     NS     206/310   2330.7±180.5      2583.9±147.2       ≥100    8   Both    Hospital, healthy                                                  English   ELISA                ([@b25-etm-0-0-3251])
  Mihu, 2013            European                       None     NS     44/44     7374.17±4701.35   11045.68±3920.93   \<100   5   Both    Hospital, Patients^[b](#tfn2-etm-0-0-3251){ref-type="table-fn"}^   English   ELISA                ([@b26-etm-0-0-3251])
  Petridou, 2003        European                       None     NS     84/84     12.37±6.25        13.53±5.26         ≥100    7   Both    Hospital, Patients^[c](#tfn3-etm-0-0-3251){ref-type="table-fn"}^   English   RIA                  ([@b27-etm-0-0-3251])
  Rzepka-Górska, 2008   European                       NS       NS     37/48     15.28±5.74        22.7±13.37         \<100   5   Both    Population, healthy                                                English   RIA                  ([@b28-etm-0-0-3251])
  Soliman, 2006         N Am                           Higher   GOTB   117/238   88.8±63.6         148.2±68.3         ≥100    7   Both    Hospital, Patients^[d](#tfn4-etm-0-0-3251){ref-type="table-fn"}^   English   ELISA                ([@b29-etm-0-0-3251])
  Tan, 2012             Asian                          None     FIGO   37/12     5.83±2.28         15.34±3.05         \<100   7   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b30-etm-0-0-3251])
  Tang, 2012            Asian                          None     FIGO   85/85     14.2±3.2          19.2±5.4           ≥100    8   Post-   Hospital, healthy                                                  Chinese   ELISA                ([@b31-etm-0-0-3251])
  Xu, 2014              Asian                          None     FIGO   56/21     5.89±0.96         16.12±2.76         \<100   6   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b32-etm-0-0-3251])
  Yurkovetsky, 2007     N Am                           None     NS     115/135   19.2±0.89         23.3±0.68          ≥100    7   Both    Population, healthy                                                English   xMAP, immune assay   ([@b33-etm-0-0-3251])
  Zhang, 2010           Asian                          Higher   FIGO   64/25     8.2±4.17          13.33±5.61         \<100   6   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b34-etm-0-0-3251])
  Zhou, 2013            Asian                          None     FIGO   36/20     5.43±2.45         15.43±2.56         \<100   7   Both    Hospital, healthy                                                  Chinese   ELISA                ([@b35-etm-0-0-3251])

Case relative to control.

Patients without gynecological pathology or inflammatory disorders.

Patients with minor gynecologic problems.

Patients without history of cancer. SD, standard deviation; N Am, North American; NS, not stated; GOTB, the Gynecologic Oncology Tumor Bank; FIGO, International Federation of Gynecology and Obstetrics; RIA, radioimmunoassay; ELISA, enzyme linked immunosorbent assay.

###### 

Characteristics of eligible studies in this meta-analysis depending on grade.

                        No. cases   Adiponectin level (mean ± standard deviation)                                               
  --------------------- ----------- ----------------------------------------------- ---- ------------ ------------ ------------ -----------------------
  Fu, 2012              6           24                                              5    6.1±0.7      7.9±1.4      9.6±1.2      ([@b22-etm-0-0-3251])
  Wang, 2013            74          42                                              19   13.2±1.2     9.6±1.4      6.2±0.9      ([@b23-etm-0-0-3251])
  Li, 2011              17          62                                              27   6.37±0.61    6.89±0.62    6.45±0.59    ([@b24-etm-0-0-3251])
  Rzepka-Górska, 2008   12          13                                              8    19.04±9.43   13.48±5.95   12.86±1.25   ([@b28-etm-0-0-3251])
  Tan, 2012             12          37                                              10   7.98±2.18    5.49±1.48    3.74±0.65    ([@b30-etm-0-0-3251])
  Xu, 2014              27          19                                              10   6.06±0.72    6.83±0.75    6.22±0.94    ([@b32-etm-0-0-3251])
  Zhang, 2010           40          17                                              7    9.31±4.65    7.11±2.18    4.47±1.35    ([@b34-etm-0-0-3251])

###### 

Stratified meta-analysis of circulating adiponectin levels and endometrial cancer.

                                Endometrial cancer (N)                                         
  ----------------------- ----- ------------------------ ------ ---------------------- ------- ------
  All studies             20    2337                     3355   −1.96 (−2.60, −1.31)   0.000   98.9
  Study size                                                                                   
    \<100                 10    420                      294    −2.58 (−3.57, −1.60)   0.000   96.0
    ≥100                  10    1917                     3061   −1.37 (−2.28, −0.46)   0.003   99.4
  Study quality                                                                                
    Low (score \<7)         5   263                      158    −2.81 (−4.46, −1.16)   0.001   97.5
    High (score ≥7)       15    2074                     3197   −1.70 (−2.44, −0.96)   0.000   99.1
  Ethnicity                                                                                    
    Asia                  12    911                      882    −2.48 (−3.97, −0.99)   0.001   99.1
    Europe                  3   165                      176    −0.52 (−0.90, −0.14)   0.007   65.1
    North America           5   1261                     2297   −1.71 (−2.60, −0.82)   0.000   99.2
  Pre-/post-menopause                                                                          
    Both                  14    1556                     2098   −1.95 (−2.81, −1.08)   0.000   98.9
    Pre-                    2   141                      292    −1.52 (−3.49, 0.45)    0.131   95.9
    Post-                   4   640                      965    −2.27 (−4.36, −0.18)   0.033   99.3
  Laboratory assay                                                                             
    ELISA                 17    2101                     3088   −1.94 (−2.62, −1.26)   0.000   98.9
    RIA                     2   121                      132    −1.96 (−2.60, −1.31)   0.086   68.6
    xMAP                    1   115                      135    −5.23 (−5.76, −4.71)   --      --
  Control source                                                                               
    Hospital              15    1156                     1248   −2.09 (−3.12, −1.06)   0.000   98.9
    Population              5   1181                     2107   −1.68 (−2.63, −0.72)   0.001   99.2
  Control status                                                                               
    Healthy               17    2063                     3077   −1.83 (−2.48, −1.17)   0.000   98.8
    Patients without EC     3   274                      278    −2.65 (−6.13, 0.85)    0.137   99.5
  Publication language                                                                         
    English               10    1778                     2933   −1.86 (−2.57, −1.14)   0.000   99.0
    Chinese               10    559                      422    −2.13 (−3.91, −0.34)   0.019   98.9

Random effects data are presented as the standardized mean difference (95% confidence interval). RIA, radioimmunoassay; EC, endometrial cancer.

[^1]: Contributed equally
